Ex Vivo Study of Immune-Reconstitution Kinetics in HIV-infected ARV-naive Subjects, With Advanced Disease, Starting a Darunavir/Ritonavir or Efavirenz Based HAART (IMMUNO Study)

Trial Profile

Ex Vivo Study of Immune-Reconstitution Kinetics in HIV-infected ARV-naive Subjects, With Advanced Disease, Starting a Darunavir/Ritonavir or Efavirenz Based HAART (IMMUNO Study)

Completed
Phase of Trial: Phase IV

Latest Information Update: 25 Nov 2013

At a glance

  • Drugs Darunavir/ritonavir (Primary) ; Efavirenz (Primary) ; Emtricitabine/tenofovir disoproxil fumarate
  • Indications HIV infections
  • Focus Therapeutic Use
  • Acronyms IMMUNO
  • Sponsors Janssen-Cilag
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 05 Aug 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 07 Mar 2013 Planned end date changed from 1 Dec 2013 to 1 Jun 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top